American Century Companies
TCRX icon

American Century Companies’s TScan Therapeutics TCRX Stock Holding History

American Century Companies’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-47,481
Closed -$278K – 2957
2024
Q2 		$278K Buy
47,481
+15,596
+49% +$123K ﹤0.01% 2663
2024
Q1 		$253K Buy
31,885
+10,570
+50% +$66.5K ﹤0.01% 2701
2023
Q4 		$124K Buy
21,315
+2,103
+11% +$9.63K ﹤0.01% 2786
2023
Q3 		$49.2K Buy
+19,212
New +$44.8K ﹤0.01% 2808

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

American Century Companies's TCRX Position: Q3 2024 in Review

American Century Companies sold out of TScan Therapeutics (TCRX) in Q3 2024, closing a stake of 47,481 shares — an estimated $278K sold.

American Century Companies first reported a position in TCRX in Q3 2023 and held it in 4 quarters. The position peaked at $278K in Q2 2024. 89 funds tracked by Wall St. Rank hold TCRX as of Q3 2024.

  • American Century Companies reported no remaining TScan Therapeutics position as of Q3 2024 after selling out during the quarter.
  • American Century Companies sold 47,481 TScan Therapeutics shares in Q3 2024, an estimated $278K.
  • American Century Companies first reported a position in TScan Therapeutics in Q3 2023 and held it in 4 quarters.
  • American Century Companies's TScan Therapeutics position peaked at $278K in Q2 2024.
  • 89 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2024.

Based on American Century Companies's 13F filing for Q3 2024, filed 12 Nov 2024.